Memphasys Ltd (ASX:MEM, OTC:MPHSF, FRA:IG7) has executed a 12-month exclusive national supply agreement with Monash IVF Group Ltd (ASX:MVF) (ASX) for the rollout of its Felix™ automated sperm selection system across Australia.
The agreement follows more than 10 years of collaboration between the companies and comes after Monash IVF conducted the pivotal Felix clinical trial, which concluded in 2025.
The deal represented the largest commercial arrangement for Felix to date and marked a key step in its transition from product validation to scaled commercial deployment.
Agreement follows clinical validation
Felix will initially be deployed at two Monash IVF Group clinics during a 3-month rollout phase.
This stage will include implementation, staff training, system troubleshooting and the collection of embryology and clinical outcome data.
If the initial rollout is completed successfully, the full 12-month supply term will begin, enabling national deployment across Monash IVF’s Australian clinic network.
Monash IVF operates 22 clinics across all mainland capital cities and reported 12,085 stimulated IVF cycles in FY2025, with most involving intracytoplasmic sperm injection, or ICSI.
Terms support recurring revenue model
Commercial terms of the agreement remain confidential, but Memphasys said the contract was expected to support significant ongoing revenue generation through the supply of Felix cartridges and consoles.
Initial delivery of cartridges and consoles is expected to begin immediately as part of the rollout phase.
The agreement also includes a quarterly ordering schedule, giving Memphasys greater visibility over production planning and cash flow.
Performance reviews and good-faith extension negotiations provide a pathway for expansion beyond the initial 12-month term, subject to adoption across Monash IVF’s network.
Anchor customer for Australian commercialisation
Memphasys said the agreement provided an anchor customer deployment in Australia and a reference site for broader market expansion.
The company has secured inclusion of Felix on the Australian Register of Therapeutic Goods, allowing commercial deployment in Australia.
“Executing this agreement with Monash IVF is a significant commercial milestone for Memphasys, validating both the clinical value of Felix and our commercialisation strategy,” Memphasys Commercialisation Committee chair Marjan Mikel said.
“Beyond the contracted revenue opportunity, Monash IVF provides a world-class reference customer and a strong platform to support broader adoption of Felix across Australia and international markets.”
Strategy targets local and international growth
Memphasys said Australia was a strategically important market for Felix, with more than 60,000 fresh IVF cycles performed annually.
The Monash IVF agreement adds to the company’s growing commercial footprint, with Felix now positioned across Australia, Europe, the Middle East and North Africa, India, Japan and Southeast Asia.
The company said Monash IVF’s clinical standing could support broader adoption of Felix in existing and new markets.
Memphasys has also established manufacturing capacity, supply chain infrastructure and quality systems to support the Monash IVF agreement and future growth opportunities.
What comes next
The next step is the three-month implementation phase at the initial two Monash IVF clinics.
Subject to successful completion and final site confirmation, Felix will then be rolled out across Monash IVF’s national network under the 12-month supply agreement.
Memphasys also expects the outcomes of the pivotal Monash IVF clinical trial to be published in the near future, providing further independent validation of Felix against conventional sperm selection methods.
About Memphasys
Memphasys is an Australian reproductive biotechnology company commercialising the Felix System, a patented bio-separation technology designed to isolate viable sperm cells for assisted reproduction.
The system combines electrophoresis and size-exclusion membranes to provide a fast, gentle and standardised sperm selection process.
Memphasys’ commercial strategy is focused on building contracted sales through direct and distribution-led channels, scaling production to improve margins and positioning Felix as a new global standard in sperm preparation for assisted reproductive technology procedures.